HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss.

@article{Schpbach2005HIV1PM,
  title={HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss.},
  author={J{\"o}rg Sch{\"u}pbach and Huldrych F. G{\"u}nthard and Beda Joos and Marek Fischer and J{\"u}rg B{\"o}ni and Zuzana Tomasik and Sabine Yerly and Luc Perrin and Manuel Battegay and Hansjakob Furrer and Pietro Vernazza and Enos Bernasconi and Bernard Hirschel},
  journal={Journal of acquired immune deficiency syndromes},
  year={2005},
  volume={40 3},
  pages={250-6}
}
The dynamics of HIV-1 RNA during structured treatment interruptions (STIs) are well established, but little is known about viral proteins like p24. We studied 65 participants of an STI trial. Before the trial, continuous highly active antiretroviral therapy (HAART) had suppressed their viral load to <50 copies/mL during 6 months. They then interrupted HAART during weeks 1 through 2, 11 through 12, 21 through 22, 31 through 32, and 41 through 52. The p24 was measured by boosted enzyme-linked… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

Similar Papers

Loading similar papers…